Crossover Backing Has Little-To-No Impact On Post-IPO Performance
This article was originally published in Start Up
Executive Summary
Based on a review of recent biotech IPOs, biopharma companies with crossover investors experienced virtually the same step-up in valuation as those firms without crossover backers, and only slightly higher average stock prices six months post-IPO.
You may also be interested in...
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.